Grape King Bio Ltd. · TWSE:1707
Grape King Bio — Q4 2023 Earnings Presentation
28 slides from Grape King Bio's earnings presentation, Jan 24, 2024
Slide 1: Grape King Bio Investor Presentation
Grape King Bio(1707TT/TW) Investor Presentation January 24th ,2024
Slide 2: Company Milestones
Company Milestones 2019 2 2014 • Grape King Bio- 1991 2009 • Dr. Andrew Tseng 2015 Tech Research succeeded his Institute was Grape King is Bio Engineering Center was established. Pro-Partner’s 2013 father to become selected as 2017 established. 2021 ranked No.6 among the CEO and Forbes “Asia's • Gra
Slide 3: 2023 Revenue & 9M23 Operation Results
I@] fal selt FIX _- 2023 Revenue & 9M23 < Operation Results
Slide 4: Grape King Three Core Business Units
Grape King Three Core Business Units 4 1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM Locus of all key ingredient design, formulation, and production for the whole Group. 2. Pro-Partner (60%-own) Taiwan direct selling distribution 9M23 A differentiated distribution channel with
Slide 5: EPS and Revenue by BU
5 EPS Revenue by BU Unit:NT$ -%Flattish Unit:NT$mn 7.00 12,000 6.65 6.65 10,391 +2.4% 10,636 6.50 -1.8% 10,000 8,727 8,571 6.00 8,000 5.50 6,000 5.00 4,000 +12.9% 4.50 +46.0% 2,000 1,104 1,247 560 818 4.00 0 3.50 2022 2023 3.00 Taiwan Grape King Shanghai Grape King 9M22 9M23 Pro-Partner Consolidated
Slide 6: Five-year & 9M23 Income Statement
Five-year&9M23 Income Statement 6 (Unit:NT$mn) 2018 2019 2020 2021 2022 9M22 9M23 YoY(%) Revenue 9,183 9,239 9,168 9,798 10,391 7,267 7,435 2.3 Gross Profit 7,329 7,566 7,537 7,855 8,481 5,910 5,981 1.2 Operating Expenses (4,979) (5,231) (5,232) (5,543) (5,929) (4,181) (4,307) 3.0 Operating Profit 2
Slide 7: Dividend Payout and Capex
Dividend Payout and Capex 7 (NT$mn) 2018 2019 2020 2021 2022 2023 Net Profit 1,295 1,309 1,272 1,300 1,457 Cash Dividend 883 884 948 904 1,022 Un-disclosed Cash DPS (NT$) 6.5 6.5 6.4 6.1 6.9 Financial Forecasts Payout Ratio 67.9% 67.4% 68.5% 69.2% 70.1% EPS (NT$) 9.57 9.63 9.34 8.81 (*1) 9.84 Capex
Slide 8: Five-year & 9M23 Balance Sheet
Five-year&9M23 Balance Sheet 8 (Unit:NT$mn) 2018 2019 2020 2021 2022 9M23 Total Asset 10,648 11,359 13,104 14,061 15,053 14,081 Cash 2,050 2,146 2,927 3,635 4,673 3,519 Account Receivables 171 202 202 301 270 332 Inventory 563 546 689 719 688 758 Fixed Asset 5,927 6,454 7,308 7,208 7,360 7,318 Total
Slide 9: 1. Taiwan Grape King
9 1. Taiwan Grape King
Slide 10: Taiwan Grape King - Five-year Sales
Taiwan Grape King-Five-year 10 Unit:NT$mn Grape King Taiwan Sales 1,400 $ 1,247 $ 1,104 1,200 +13% 1,000 $ 914 +21% YoY YoY 800 $ 668 +37% $ 538 YoY 600 +24% YoY 400 200 - 2019 2020 2021 2022 2023
Slide 11: Taiwan Grape King - Five-year OBM Sales
Taiwan Grape King-Five-year 11 Unit:NT$mn Grape King Taiwan OBM Sales 1000 $840 800 $737 $658 +14% +12% YoY 600 $532 YoY +24% $412 YoY +29% 400 YoY 200 0 2019 2020 2021 2022 2023
Slide 12: Taiwan Grape King - Five-year ODM Sales
Taiwan Grape King-Five-year 12 Unit:NT$mn Grape King Taiwan ODM Sales 500 $407 400 $367 +11% +44% YoY 300 $255 YoY +87% 200 $137 YoY $126 100 +9% YoY 0 2019 2020 2021 2022 2023
Slide 13: Taiwan Grape King - ODM Business Comparison
Taiwan Grape King – ODM Business Comparison 13 2023 11% 2022 2023 PICS, 18% PICS, 24% P Customer Material 24% 20% P Customer Material 30% 19% 367 M 407 M Others 32% Others 33%
Slide 14: Botanical Drug GKAC Applied to USFDA for Phase II Review
Grape King’s Botanical Drug “GKAC” Has Applied 14 to the US Food and Drug Administration (USFDA) for a Phase II Clinical Trial Review • Ganoderma lucidum is a unique fungus in Taiwan, known as the "Forest Ruby," and it has significant effects in liver protection and cancer prevention and treatment.
Slide 15: 2. Pro-Partner
iT € 2. Pro-Partner
Slide 16: Pro-Partner Overview
Pro-Partner Overview 16 Four Key Figures for Pro-Partner 1 • Largest Taiwanese owned direct selling company in Taiwan based on revenue. • One of the fastest growing direct selling companies in Taiwan. (15% sales CAGR from 2008 to 2020) 3 • 3rd largest overall direct selling company in Taiwan. (2022
Slide 17: Pro-Partner 2023 Sales
Pro-Partner 2023 Sales 17 2023Q4 vs. 2022Q4 1.72% 2023Q4 vs. 2021Q4 6.53% 2023 YOY 1.79% 2023 vs. 2021 7.14% V.S. 2022 2021 -12.82% -16.43% 3.44% 2.56% 18.09% -18.41% -6.62% -0.19% 0.16% 2022 -7.71% 19.77% 8.20% V.S. 2021 2023 11.61% 2.94% 17.92% 6.31% 4.41% 21.5% -10.65% 30.69% -14.84% -1.51% 11.42
Slide 18: Deeply Cultivating Taiwan and Going International
Deeply Cultivating Taiwan and Going International 18 Pro-Partner • Pro-Partner is ready to open up overseas markets. Considering the vigorous developments of the direct selling industry in Malaysia, where will be chosen as the first preparation location to expand into. • There are 5 products that ha
Slide 19: 3. Shanghai Grape King
19 3. Shanghai Grape King
Slide 20: Grape King Shanghai
Grape King Shanghai Plant Size Covers area of 170 hectares GMP plant of 12,500 sqm 100K-level GMP qualified manufacturing site manufacturing plant (Liquid filling 10K-level) (Conform to the hygiene standards of productions for the health care products and food.)
Slide 21: One-stop OEM Service Platform
One-stop OEM Service Platform ODM/OEM One-stop service R&D Formulation design Package design Production Regulatory assistance Training assistance Logistics Declaration assistance
Slide 22: Customers of Shanghai Grape King
Customers of Shanghai Grape King 22
Slide 23: Own Brands of Shanghai Grape King
Own Brands of Shanghai Grape King 23
Slide 24: Plan & Strategy
I@) fal celt FIX Plan & Strategy
Slide 25: Taiwan Grape King - Growth Strategies
Taiwan Grape King – Growth Strategies 25 Key Objectives How to Achieve Extending Virtual Channels ✓ Continue to extend Telemarketing team with on Own Brand Business improvements on revenue and profit • Telemarketing Team efficiency. • Membership Management ✓ Keep increasing the number of members and
Slide 26: Own Brand Revenue from Virtual Channels - Actual Results
Own Brand Revenue from Virtual Channels – Actual Results 26 Telemarketing Total Members Virtual Channel Reach 164K Sales Growth 2.9x Established in 2021 Sales Grew 62% in 2022 Profit Contribution up 4.3x Profit Improvement in 9M23 180000 164K Unit: NT$mn Unit:NT$mn 160000 150K Sales +16% +13% 140000
Slide 27: Grape King Group - 2024 Expansion Plan
Grape King Group – 2024 Expansion Plan 27 • PKL line - Grape King Bio Park : Completed trial production in January 2024 • Phase II Factory- Biotech Research Institute :Expects to project contracting by Q1 2024 Expects to complete trial mass production by Q3 2025 • Channel integration in China: Expec
Slide 28: Thank You
Thank You For more information:www.grapeking.com.tw 28